MedTrace Logo

Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas

NCT02041611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-06-27

No results posted yet for this study

Summary

The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.

Conditions

Interventions

PROCEDURE

Blood collections

pts will have 6 blood collections (30ml/collection) throughout course of standard treatment

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Stuart A Grossman, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-13
Primary Completion
2013-09-02
Completion
2015-12-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02041611 on ClinicalTrials.gov